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b2-Adrenergic Receptor Activates Extracellular Signal-regulated
Kinases (ERKs) via the Small G Protein Rap1 and the
Serine/Threonine Kinase B-Raf*
John M. Schmitt and Philip J. S. Stork‡
From the Vollum Institute and the Department of Cell and Developmental Biology, Oregon Health Sciences University,
Portland, Oregon 97201
G protein-coupled receptors can induce cellular pro-
liferation by stimulating the mitogen-activated protein
(MAP) kinase cascade. Heterotrimeric G proteins are
composed of both a and bg subunits that can signal
independently to diverse intracellular signaling path-
ways including those that activate MAP kinases. In this
study, we examined the ability of isoproterenol, an ago-
nist of the b2-adrenergic receptor (b2AR), to stimulate
extracellular signal-regulated kinases (ERKs). Using
HEK293 cells, which express endogenous b2AR, we show
that isoproterenol stimulates ERKs via b2AR. This ac-
tion of isoproterenol requires cAMP-dependent protein
kinase and is insensitive to pertussis toxin, suggesting
that Gas activation of cAMP-dependent protein kinase is
required. Interestingly, b2AR activates both the small G
proteins Rap1 and Ras, but only Rap1 is capable of cou-
pling to Raf isoforms. b2AR inhibits the Ras-dependent
activation of both Raf isoforms Raf-1 and B-Raf, whereas
Rap1 activation by isoproterenol recruits and activates
B-Raf. b2AR activation of ERKs is not blocked by expres-
sion of RasN17, an interfering mutant of Ras, but is
blocked by expression of either RapN17 or Rap1GAP1,
both of which interfere with Rap1 signaling. We propose
that isoproterenol can activate ERKs via Rap1 and B-
Raf in these cells.
Cell proliferation is regulated by extracellular signals includ-
ing growth factors and hormones. Growth factors activate re-
ceptor tyrosine kinases to stimulate a number of intracellular
signaling cascades. One cascade, the MAP1 kinase (or ERK)
cascade triggers cellular proliferation through multiple mech-
anisms including inducing stimulation of progression through
the G1/S transition of the cell cycle and by activating rate-
limiting proteins involved in both DNA and protein synthesis
(1, 2). ERKs are activated in cancerous cells through the action
of proto-oncogenes like ras that lie upstream of the MAP kinase
cascade. Hormones can also activate the MAP kinase cascade
to stimulate proliferation in many cell types (3). Some hor-
mones, like insulin, act like growth factors to activate receptor
tyrosine kinases to stimulate intracellular cascades leading to
ERK (4, 5). However, most hormones act via serpentine (or
seven-transmembrane receptors), and couple to heterotrimeric
GTP-binding proteins (G proteins) to elicit their effects (6, 7).
Heterotrimeric G proteins are composed of two functional
units, an a subunit and a bg subunit. Both a and bg are
released from hormone receptors upon ligand binding and can
directly bind to and activate specific effectors. For a, one of
these effectors is adenylate cyclase. Historically a subunits
that stimulate adenylate cyclase are called as for stimulatory,
whereas those that inhibit adenylate cyclase are termed ai, for
inhibitory. Over the past 5 years, cross-talk between G protein-
coupled signaling pathways have been identified for many G
protein-coupled receptors (3, 8). The activation of MAP kinase
cascades has been established for G proteins of diverse classes,
including Gs, Gi, and Gq (9–11). For some of these, direct or
indirect involvement of cytoplasmic tyrosine kinases has been
shown (12–16). For others, association with regulatory mole-
cules like RasGAP (17) or Rap1GAP1 (18, 19) provides the
cross-talk necessary to modulate signals to the small G pro-
teins Ras or Rap1, respectively, to regulate the MAP kinase
cascade.
Perhaps the best studied mechanism of cross-talk between G
proteins and the MAP kinase cascade involves the bg subunit
of heterotrimeric G proteins. Activation of both Gq- and Gi-
coupled receptors releases bg to activate the tyrosine kinase
c-Src, which can activate Ras via the phosphorylation of the
adaptor molecule Shc, which then recruits a complex consisting
of Grb2 and SOS, the Ras-specific guanine nucleotide exchange
factor (GEF), to the membrane where it can activate Ras (20).
In some cases, a role for phosphoinositol 3-kinase g in Src
activation has been shown (21). In other cases, Src is activated
by a calcium-sensitive kinase PYK2 (12). Despite variations on
the mechanisms used, all examples of bg signaling to ERKs
require Ras activation.
Recently, the a subunits of heterotrimeric G proteins have
also been shown to signal to the MAP kinase cascade. The a
subunits of Gi and Go (which share extensive sequence homol-
ogy and PTx sensitivity) both bind to Rap1GAP1, a GTPase-
activating protein specific for a distinct small G protein Rap1
(19). Rap1 is a cell type-specific antagonist of Ras-dependent
signaling, and its inhibition by Rap1GAP1 can allow Ras to
signal effectively to ERKs. The a subunit of Gs has also been
implicated in MAP kinase activation. For example, constitu-
tively activated mutants of Gas are oncogenic (22–25). These
mutants encode an oncogene called gsp that can activate ERKs
when expressed in transfected cells. Activated Gas triggers the
synthesis of the second messenger cAMP through direct asso-
ciation with specific adenylate cyclases (26, 27). The major
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target of cAMP is the cAMP-dependent protein kinase PKA (28,
29). PKA has cell type-specific actions on MAP kinase signal-
ing. In many cell types, PKA antagonizes Ras-dependent acti-
vation of Raf-1, an ubiquitously expressed MAP kinase kinase
kinase (30–33) to inhibit cellular proliferation and Ras-depend-
ent transformation (34). In other cell types, PKA can activate
MAP kinase through a distinct pathway involving Rap1 and a
cell type-specific isoform of Raf called B-Raf (9, 35, 36). Recently,
a second enzyme target for cAMP, cAMP-GEF (or Epac), was
identified as a Rap1-specific GEF (37, 38). Therefore, in B-Raf-
expressing cells, cAMP has at least two potential mechanisms
to activate ERKs through Ras-independent pathways, one via
PKA and another through direct activation of Rap1-GEFs.
The ability of hormones that couple to Gas to activate Rap1
and ERKs has been examined in transfected cell lines overex-
pressing specific serpentine receptors. In Chinese hamster
ovary cells overexpressing the adenosine A2A receptor, adeno-
sine has been shown to activate ERKs via Rap1 (39). In
HEK293 cells, a well studied model of G protein coupling,
overexpression of b2-adrenergic receptor (b2AR) was shown to
couple to ERKs via a Ras-dependent pathway (40, 41). The best
studied receptor system coupled to Gas is the b2AR and its
activation by the agonist isoproterenol. In this study, we exam-
ine the mechanism by which isoproterenol activates ERKs in
HEK293 cells expressing endogenous levels of b2AR.
EXPERIMENTAL PROCEDURES
Materials—Antibodies to Rap1, B-Raf, Raf-1, recombinant MEK-1
protein, and agarose-conjugated antibodies to ERK1, ERK2 (c-16), and
myc-ERK were purchased from Santa Cruz Biotechnology Inc (Santa
Cruz, CA). Anti-Ras antibody was purchased from Upstate Biotechnol-
ogy, Inc. (Lake Placid, NY). Phosphorylation-specific ERK antibodies
(pERK) that recognize phosphorylated ERK1 (pERK1) and ERK2
(pERK2), at residues threonine 183 and tyrosine 185 were purchased
from New England Biolabs (Beverly, MA). Isoproterenol, thrombin,
carbachol, Flag (M2) antibody, and lysophosphatidic acid were pur-
chased from Sigma. Forskolin, clonidine, PTx, alprenolol, atenolol, epi-
dermal growth factor (EGF), AG1478, and N-[2-(p-bromocin-
namylamino) ethyl]-5-isoquinolinesulfonamide (H89) were purchased
from Cal Biochem (Riverside, CA). Nickel-nitrilotriacetic acid-agarose
was purchased from Qiagen Inc. (Chatswoth, CA). Radioisotopes were
from NEN Life Science Products.
Cell Culture—HEK293 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) plus 10% fetal calf serum at 37 °C in 5% CO2.
Cells were maintained in serum-free DMEM for 16 h at 37 °C in 5% CO2
prior to treatment with various reagents for both immune complex
assays and Western blotting. Cells pre-treated with PTx (100 ng/ml)
were incubated in serum-free media for 16 h prior to stimulations. All
inhibitors, unless otherwise indicated, were added to cells 20 min prior
to treatment.
Western Blotting—Cell lysates were prepared as described (9). Cell
lysate protein concentrations were quantified using Bradford protein
assay. For detection of B-Raf, ERK2, myc-ERK, Rap1, Flag, Ras, and
phospho-ERK1/2 (pERK), equal protein amounts of cell lysate per treat-
ment condition were resolved by SDS-polyacrylamide gel electrophore-
sis, blotted onto polyvinylidene difluoride (Millipore Corp., Bedford,
MA) membranes and probed with the corresponding antibodies accord-
ing to the manufacturer’s guidelines.
Plasmids and Transfections—Seventy to 80% confluent HEK293
cells were co-transfected with the indicated cDNAs using a Lipo-
fectAMINE kit (Life Technologies, Inc.) according to the manufacturer’s
instructions. The control vector, pcDNA3 (Invitrogen Corp.), was in-
cluded in each set of transfections to assure that each plate received the
same amount of DNA. Following transfection, cells were allowed to
recover in serum-containing media for 24 h. Cells were then starved
overnight in serum-free DMEM before treatment and lysis.
Immune Complex Assays—For ERK assays, all cell treatments were
lysed in ice-cold lysis buffer (50 mM Tris-HCl, pH 8.0, 10% glycerol, 1%
Nonidet P-40, 200 mM NaCl, 2.5 mM MgCl2, 1 mM phenylmethylsulfonyl
fluoride, 1 mM leupeptin, 10 mg/ml soybean trypsin inhibitor, 10 mM
NaF, 0.1 mM aprotinin, and 1 mM NaVO4). The lysates were centrifuged
at low speed to remove nuclei, and the supernatant was examined for
ERK activity using myelin basic protein (MBP) as a substrate and
[g-32P]ATP as a phosphate donor with equal protein amounts per assay
condition as described (9). For B-Raf assays, untreated and treated cells
were lysed in ice-cold 1% Nonidet P-40 buffer containing 10 mM Tris, pH
7.4, 5 mM EDTA, 50 mM NaCl, and 1 mM phenylmethylsulfonyl fluoride.
Immune complex kinase assays were performed as described (9) using
MEK-1 as a substrate and [g-32P]ATP as a phosphate donor with equal
protein amounts per assay. The reaction products of all kinase assays
were resolved by 10% SDS-polyacrylamide gel and analyzed with a
PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
Nickel Affinity Chromatography—Experiments utilizing polyhisti-
dine-tagged Rap1 (His-Rap1 and His-RapV12) and Ras (His-Ras), were
performed by transfecting HEK293 cells using LipofectAMINE reagent.
Cells were lysed in ice-cold buffer containing 1% Nonidet P-40, 10 mM
Tris, pH 8.0, 20 mM NaCl, 30 mM MgCl2, 1 mM phenylmethylsulfonyl
fluoride, and 0.5 mg/ml aprotinin. Supernatants were prepared by low
speed centrifugation. Transfected His-tagged proteins were precipi-
tated from supernatants containing equal amounts of protein using
nickel-nitrilotriacetic acid-agarose and washed with 20 mM imidazole in
lysis buffer and eluted with 500 mM imidazole and 5 mM EDTA in
phosphate-buffered saline. One-half of the eluates containing His-
tagged proteins were separated on SDS-polyacrylamide gel electro-
phoresis, and B-Raf or Raf-1 proteins were detected by Western blotting
(9). The remaining His-Rap1 eluates, of equal amounts, were immuno-
precipitated with B-Raf antisera, and B-Raf kinase activity was meas-
ured by immune complex assay. Equal amounts of His-Rap1 and His-
Ras was confirmed by Western blotting.
Affinity Assay for Rap1 Activation in HEK293 Cells—GST fusion
protein of the Rap1-binding domain of RalGDS was expressed in Esch-
erichia coli following induction by isopropyl-1thio-b-D-galactopyrano-
side (GST-RalGDS was a gift from Dr. Bos (Utrecht University,
Utrecht, The Netherlands) to P. J. S. S.). Bacterial lysates were pre-
pared, and GST fusion proteins were immobilized by incubating lysates
for 1 h at 4 °C with glutathione-Sepharose. Sepharose beads were
washed three times in order to remove excess GST fusion protein.
HEK293 cells were grown as described, and were stimulated at 37 °C
for the indicated times and immediately lysed in ice-cold lysis buffer (50
mM Tris-HCl, pH 8.0, 10% glycerol, 1% Nonidet P-40, 200 mM NaCl, 2.5
mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, 10
mg/ml soybean trypsin inhibitor, 10 mM NaF, 0.1 mM aprotinin, and 1
mM NaVO4). Active Rap1 was isolated using methods as described by
Franke et al. (42). Briefly, cell lysates were cleared by centrifugation,
and equal amounts of supernatants were incubated with GST-RalGDS-
Rap1 binding domain pre-coupled to glutathione beads. Following a 1-h
incubation at 4 °C, beads were pelleted and rinsed threes times with
ice-cold lysis buffer, protein was eluted from the beads using 23 Laemmli
buffer and applied to a 12% SDS-polyacrylamide gel. Proteins were trans-
ferred to polyvinylidene difluoride membrane, blocked in 5% milk for 1 h,
and probed with a-Rap1/Krev-1 or Flag (M2) antibody overnight at 4 °C,
followed by a horseradish peroxidase-conjugated anti-rabbit secondary
antibody. Proteins were detected using enhanced chemiluminescence.
Affinity Assay for Ras Activation in HEK293 Cells—HEK293 cells
were grown as described, and were stimulated at 37 °C for the indicated
times and immediately lysed in ice-cold lysis buffer (50 mM Tris-HCl,
pH 8.0, 10% glycerol, 1% Nonidet P-40, 200 mM NaCl, 2.5 mM MgCl2, 1
mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, 10 mg/ml soybean
trypsin inhibitor, 10 mM NaF, 0.1 mM aprotinin, and 1 mM NaVO4).
Following the manufacturer’s recommended protocol, activated Ras was
isolated from stimulated lysates using agarose-coupled GST-Raf1-RBD
provided in the Ras activation assay kit (Upstate Biotechnology, Inc.).
Proteins were eluted from the beads using 23 Laemmli buffer and
applied to a 12% SDS-polyacrylamide gel. Proteins were transferred to
polyvinylidene difluoride membrane, blocked in 5% milk for 1 h, and
probed with a-Ras antibody overnight at 4 °C, followed by a horseradish
peroxidase-conjugated anti-mouse secondary antibody. Proteins were
detected using enhanced chemiluminescence.
RESULTS
Isoproterenol Activates ERK via Endogenous b2ARs—Isopro-
terenol treatment of HEK293 cells with the b-adrenergic ago-
nist, isoproterenol, induces phosphorylation of MAP kinase
ERK in a dose-dependent manner (Fig. 1A). Three-minute
stimulations with increasing concentrations of isoproterenol,
revealed maximal ERK kinase activity at concentrations over
10 mM. Similar to previously published data, 10 mM isoprotere-
nol induced endogenous ERK kinase activity maximally be-
tween 3 and 5 min (Fig. 1B) (43). Isoproterenol-induced ERK
kinase activation was completely blocked by pretreatment with
the selective b1,2-adrenergic antagonist alprenolol (Fig. 1C).
Pretreatment with the selective b1-adrenergic antagonist,
atenolol, did not inhibit isoproterenol-mediated activation of
MAP kinase. These results suggest that isoproterenol activates
ERKs via endogenously expressed b2ARs with maximal activa-
tion between 3 and 5 min.
b2ARs mediate their intracellular signals via Gas, which,
upon isoproterenol binding is released to activate adenylate
cyclase. This results in the rapid elevation of intracellular
cAMP levels and activation of the cAMP-dependent protein
kinase PKA. To determine whether PKA plays a role in medi-
ating endogenous ERK activation we utilized the selective PKA
inhibitor H89 (44). Pretreatment of serum-starved HEK293
cells with H89 completely eliminated the ability of isoprotere-
nol to activate ERK kinase (Fig. 2). As a positive control, we
treated cells with forskolin, an activator of adenylate cyclase.
Forskolin activated ERKs, and H89 abolished forskolin activa-
tion of ERKs (Fig. 2). Taken together, the above data demon-
strate that isoproterenol activates endogenous signaling path-
ways that utilize both the b2AR and the cAMP-dependent
kinase PKA.
ERK Activation by Isoproterenol Is Insensitive to PTx Treat-
ment —Recent reports using HEK293 cells transiently trans-
fected with cDNA encoding the b2AR have shown that isopro-
terenol-induced activation of ERK was blocked by PTx (41, 45).
These data imply that ERK activation utilizes a Gai (or Gao)
pathway to stimulate ERK activity. To investigate whether
b2AR can activate endogenous signaling pathways in the pres-
ence of PTx, we pretreated HEK293 cells overnight with PTx
and assessed the ability of isoproterenol to activate endogenous
ERKs. In an extended time course measuring ERK activation
by isoproterenol, no differences between PTx-treated cells and
untreated cells were seen (Fig. 3A). ERK activation following
treatment of HEK293 cells with both the muscarinic agonist
carbachol (Fig. 3A) and lysophosphatidic acid (data not shown)
was blocked by PTx, consistent with their ability to couple to
Gai. To further confirm that the activation of ERKs by isopro-
terenol was insensitive to PTx, immune complex kinases as-
says were performed on endogenous ERK1/2. As can be seen in
Fig. 3B, isoproterenol’s activation of ERKs was not blocked by
PTx. However, activation of ERKs by the a-adrenergic receptor
agonist, clonidine, was blocked by PTx. As a negative control,
FIG. 2. Endogenous b2-adrenergic receptors in HEK293 cells
activate ERKs via PKA. Serum-starved HEK293 cells were treated
with isoproterenol for 3 min or forskolin for 5 min in the absence or
presence of the PKA inhibitor H89 (10 mM), as indicated. Cells were
then lysed, and equal protein amounts per treatment condition were
used for Western blot with pERK or kinase assay using MBP as a
substrate. A representative experiment showing both pERK (upper
panel) and kinase activity (middle panel) is shown. The lower panel
demonstrates equal protein levels as evidenced by Western blot probed
for ERK2.
FIG. 3. b2AR-mediated activation of ERKs via endogenous re-
ceptors is insensitive to PTx. A, HEK293 cells were serum-starved
and received either no pretreatment or pretreatment with 100 ng/ml
PTx for 16 h. Cells were then stimulated with 10 mM isoproterenol for
the indicated times. As negative and positive controls, respectively,
HEK293 cells were also treated with 100 ng/ml EGF for 5 min and 10
mM carbachol for 5 min in the presence or absence of PTx. HEK293 cells
were lysed, and equal amounts of protein were analyzed by Western
blotting with pERK antibody (upper panel). B, HEK293 cells were
prepared similarly to those in panel A with PTx pre-treatment for 16 h.
Cells were then treated with 10 mM isoproterenol for 3 min, 100 ng/ml
EGF for 5 min, and 50 mM clonidine for 5 min. Cells were lysed, and
endogenous ERK1/2 were immunoprecipitated from equivalent
amounts of protein using agarose-coupled ERK antibodies (as in Fig.
1B). A representative immune complex kinase assay with the location
and phosphorylation of the MBP substrate is shown (upper panel). The
lower panel represents a Western blot identifying the levels of ERK2 to
control for protein loading.
FIG. 1. ERK activation by b2AR. A, isoproterenol dose response of
phosphorylated ERKs (pERK). HEK293 cells were serum-starved and
treated with increasing concentrations of isoproterenol for 3 min. Cell
lysates were prepared as detailed under “Experimental Procedures.” B,
time course of endogenous ERK activation following isoproterenol stim-
ulation in HEK293 cells. HEK293 cells were harvested for either im-
mune complex kinase assay using MBP as a substrate or Western
blotting, using phosphospecific ERK1/2 (pERK) antibodies. Cells were
treated with isoproterenol or EGF, as indicated. Upper panel, a repre-
sentative Western blot probed with pERK antibody. Middle panel, a
representative autoradiogram with the position of MBP shown. Lower
panel, Western blotting showing equal loading of protein amounts
within cell lysate was performed using ERK2 antibody. C, blockade of
isoproterenol stimulation of pERK. Serum-starved cells were treated
with isoproterenol following a 10-min pretreatment with either atenolol
or alprenolol. Upper panel, a representative Western blot probed with
pERK antibody. Bottom panel, equal amounts of protein were utilized
as evidenced by the Western blot probed with ERK2 antibody.
we show that EGF-mediated activation of ERKs was not
blocked by PTx (Fig. 3A). These results would indicate that
b2AR is able to activate endogenous ERKs via a Gai/Gao-inde-
pendent pathway.
ERK Activation by b2AR Requires Rap1—Recent studies
have identified a role for Rap1 in signaling via G proteins (9,
18, 19). Therefore, we sought to determine whether endogenous
b2AR stimulation by isoproterenol could activate Rap1. To de-
termine whether Rap1 was activated in response to isoproter-
enol treatment, we performed a time course of Rap1 activation.
Endogenous Rap1 was activated at the earliest time point
examined with maximal activation observed from 3 to 5 min,
and a return to base line by 20 min (Fig. 4A). As previously
demonstrated, thrombin was also able to induce endogenous
Rap1 activity in these cells (39). To investigate the requirement
for PKA in activating Rap1, cells were pretreated with H89.
Pretreatment of HEK293 cells with 10 mM H89 blocked the
ability of either forskolin or isoproterenol to activate Rap1 at 3
min, but had no effect on thrombin’s action (Fig. 4B). Taken
together, these results would suggest that b2AR activates Rap1
in a PKA-dependent manner. Recent studies have suggested
that the guanine-nucleotide exchange factor, C3G, may play a
role in activating Rap1 (46). C3G is constitutively associated
with a member of the Crk adaptor family and is stabilized by its
association with Crk-L (47). As can be seen in Fig. 4C, cotrans-
fection of Flag-Rap1 along with Crk-L and C3G results in Rap1
activation in HEK293 cells as in other cell types (47). To de-
termine whether C3G is playing a role in activating Rap1 in
response to isoproterenol we used a truncated mutant of C3G
containing the CRK-binding region, CBR, which interferes
with CRK function (46, 47). Transfection of CBR along with
Flag-Rap1 blocked the ability of isoproterenol to activate Rap1
(Fig. 4C). To further confirm the role for PKA in activating
Rap1 in response to isoproterenol we co-transfected the PKA-
specific inhibitory protein, PKI, which abolished the ability of
isoproterenol to activate Rap1 (Fig. 4C). These results would
suggest that Rap activation in response to b2AR stimulation is
PKA-dependent and also utilizes the guanine-nucleotide ex-
change factor C3G. Indeed, HEK293 cells express endogenous
levels of C3G (Fig. 4D) raising the possibility that the b2AR
may utilize C3G to activate Rap1.
Recent data have suggested that the small G protein Ras
may play a role in mediating ERK activation by b2AR (41, 48).
To examine the ability of b2AR to activate Ras, we examined a
time course of Ras activation. Similar to Rap1 activation, Ras
appeared to be activated very early following isoproterenol
stimulation and was inactive by 5–10 min (Fig. 5A). HEK293
cells were treated with EGF as a positive control for Ras acti-
vation. To determine whether Ras activation was PKA-depend-
ent, HEK293 cells were pretreated with H89 and stimulated
with isoproterenol. H89 pretreatment had no effect on Ras
activation (Fig. 5B), suggesting that Ras is activated by isopro-
terenol in a PKA-independent fashion. Consistent with this
result, forskolin did not activate Ras. Moreover, EGF stimula-
tion of Ras was not blocked by H89, suggesting that H89’s effect
was specific for PKA. These data would indicate that Ras
activation by b2AR did not require cAMP or PKA and suggests
that Gas stimulation of adenylate cyclase was not directly
involved in Ras activation.
Based on the finding that both Rap1 and Ras were rapidly
activated in response to isoproterenol treatment, we next ex-
amined the role of these small G proteins in mediating ERK
activation. HEK293 cells were transiently transfected with
cDNAs encoding an interfering mutant of Rap1, RapN17, the
Rap1 antagonist Rap1GAP1, and the interfering mutant of
Ras, RasN17. These mutants have previously been character-
ized by our laboratory and others and function as selective
blockers of Rap1 or Ras signaling (9, 49, 50).2 Cells transfected
2 K. D. Carey, J. M. Schmitt, A. M. Baird, T. J. Dillon, A. D. Holdorf,
A. S. Shaw, and P. J. S. Stork, submitted for publication.
FIG. 4. Isoproterenol activation of Rap1. A, time course of acti-
vation of Rap1 by isoproterenol. Serum-starved HEK293 cells were
treated with 10 mM isoproterenol or 0.1 unit/ml thrombin for the indi-
cated times. Equal amounts of cell lysate were incubated with pre-
coupled GST-RalGDS protein, and analyzed by Western blot for GTP-
loaded Rap1. HEK293 cell lysate was used to indicate the position of
Rap1. B, isoproterenol activation of Rap1 is sensitive to H89. Cells were
stimulated with 10 mM isoproterenol for 3 min and 10 mM forskolin for
5 min, following a pretreatment with H89 (10 mM); equal amounts of cell
lysate were used to assay for GTP-loaded Rap1. Thrombin was used as
a positive control for Rap1 activation and a negative control for H89. C,
isoproterenol activation of Rap is sensitive to PKI and CBR. HEK293
cells were co-transfected with Flag-Rap1 and the indicated cDNAs,
serum-starved, and stimulated with 10 mM isoproterenol for 3 min. Cells
transfected with Crk-L/C3G were not stimulated. Equal amounts of cell
lysate were incubated to assay for GTP-loaded Rap1 using GST-Ral-
GDS and a Flag (M2) antibody to identify Flag-Rap1 protein. D,
HEK293 cells express C3G. Western blotting of equal amounts of pro-
tein were used to represent cell lysates from various cell types: COS 7
(lane 1), PC12 (lane 2), and HEK293 (lane 3).
FIG. 5. Isoproterenol activation of Ras. A, time course of activa-
tion of Ras by isoproterenol. HEK293 cells were serum-starved and
treated with 10 mM isoproterenol or 100 ng/ml EGF for the indicated
times. Equal quantities of cell lysate were incubated with GST-
Raf1RBD, and analyzed by Western blot for GTP-loaded Ras. HEK293
cell lysate was used to indicate the position of Ras. B, isoproterenol
activation of Ras is insensitive to H89. Serum-starved HEK293 cells
were treated with isoproterenol for 3 min, 10 mM forskolin for 5 min, or
100 ng/ml EGF for 5 min following a pretreatment with H89 (10 mM);
equal amounts of cell lysate were used to assay for GTP-loaded Ras.
EGF was used as a control for Ras activation.
with myc-ERK and stimulated with 10 mM isoproterenol for 3
min displayed robust ERK kinase activity (Fig. 6A). Isoproter-
enol-induced ERK activation was significantly reduced when
cells were co-transfected with either RapN17 or Rap1GAP1.
RasN17 did not appear to have a significant effect (Fig. 6A).
The differences in kinase activity were not attributed to vary-
ing levels of myc-ERK expression (Fig. 6A, lower panel). Quan-
tification of three independent experiments revealed that ERK
kinase activity, induced by isoproterenol for 3 min, was signif-
icantly reduced by either RapN17 or Rap1GAP1 (Fig. 6B).
These data indicate that endogenous Rap1, but not endogenous
Ras, is required for b2AR to activate MAP kinase at this time
point.
Isoproterenol Induces Rap1/B-Raf Association and B-Raf
Kinase Activity—To further investigate the function of active
Rap1 in mediating MAP kinase activation in HEK293 cells, we
examined the downstream target of Rap1, B-Raf. Prior studies
from our laboratory have demonstrated in PC12 cells, which
express high levels of B-Raf, that cAMP is able to activate
ERKs through a PKA/Rap1/B-Raf pathway (9). HEK293 cells
also express high levels of endogenous B-Raf protein (Fig. 7A).
HEK293 cells were left untransfected or transfected with His-
Rap or a constitutively active mutant of His-Rap, His-RapV12
(9, 52), serum-starved, and treated with isoproterenol for 3 min
in the absence or presence of H89. Isoproterenol stimulation
induced Rap1/B-Raf association and B-Raf kinase activity (Fig.
7B). Both the association and kinase activity was blocked by
the PKA inhibitor H89. Results from three independent exper-
iments are shown in Fig. 7C.
Isoproterenol stimulation of HEK293 cells induced the acti-
vation of Ras (Fig. 5A). To determine whether active Ras could
couple to relevant downstream effectors, we investigated its
ability to associate with the Raf isoforms B-Raf and Raf-1.
Previous studies have suggested that recruitment of Raf to Ras
is necessary for its activation (53–56). HEK293 cells were
transfected with His-tagged Ras cDNA (His-Ras) and treated
with either isoproterenol or EGF, or pretreated with isoproter-
enol and then treated with EGF. Results presented in Fig. 7D
suggest that isoproterenol stimulation did not induce the asso-
ciation of endogenous Raf-1 with Ras. More importantly, pre-
treatment with isoproterenol inhibited the ability of EGF to
induce the association of endogenous Raf-1 with Ras (Fig. 7D).
Parallel experiments examining the association of B-Raf with
Ras indicated that isoproterenol alone inhibited basal as well
as EGF-induced association of B-Raf with Ras (Fig. 7E). These
results suggest that, although Ras is activated by b2AR, it is
unable to couple to either Raf-1 or B-Raf kinases.
ERK Activation by b2AR Occurs Independently of EGF Re-
ceptor Phosphorylation —A recent study has suggested a role
for the EGF receptor in mediating b2AR-induced ERK activa-
tion (57). To address the requirement for the EGF receptor in
b2AR signaling, we treated cells with the EGF receptor kinase
inhibitor AG1478, which specifically inhibits kinase activity
of the receptor. Pretreatment of cells with AG1478 did not
block isoproterenol-induced activation of endogenous ERKs
(Fig. 8A). The above results would suggest that Rap1-depend-
ent activation of ERKs by b2AR does not require EGF recep-
tor transactivation.
Recent studies have also suggested that the activation of Ras
by b2AR may also utilize the EGF receptor, via non-classical
coupling to Gai (57). To further elucidate the mechanism by
which Ras is activated by b2AR, we determined whether en-
dogenous Ras activation by isoproterenol was dependent on
EGF receptor activation. Pretreatment of HEK293 cells with
AG1478 did not block Ras activation by isoproterenol at 3 min
(Fig. 8B). To investigate the possibility that Gai may signal to
Ras, we pretreated HEK293 cells with PTx and stimulated cells
with either isoproterenol or carbachol for 3 and 5 min, respec-
tively. Representative data presented in Fig. 8C demonstrate
that Ras activation by isoproterenol, but not by carbachol, was
insensitive to PTx. As a positive control, we show that Ras
activation by carbachol was sensitive to PTx (Fig. 8C). The
above data as well as that presented in Fig. 5A indicate that
Ras is activated by the endogenous b2AR independently of
either the EGF receptor or Gai.
DISCUSSION
The second messenger cAMP is the best studied intracellular
signal. Its major action, the activation of PKA (28, 29) allows
hormonal signals to couple to intracellular phosphorylation
events. Hormonal elevation of cAMP levels is triggered by the
specific heterotrimeric G protein subunit Gas. The range of
extracellular ligands that couple to Gas is extensive and in-
cludes moderately sized peptides, including vasoactive intesti-
nal peptide-like, members of the glucagon/secretin superfam-
ily, adrenocorticotropic hormone, parathyroid stimulating
hormone, and a large family of hypothalamic releasing factors,
as well as the family of large glycoproteins thyroid stimulating
hormone, follicle-stimulating hormone, and luteinizing hor-
mone. Small molecules can also activate Gs to stimulate adeny-
late cyclases, including dopamine (via the D1 receptor), aden-
osine (via the A2A receptor), prostaglandin E, and the family of
adrenergic molecules, including epinephrine and norepineph-
rine (58–60). The cognate receptors for all these ligands are
heptahelical transmembrane proteins (also called serpentine
receptors) that associate with Gas.
FIG. 6. b2AR-mediated activation of ERKs requires Rap1. A, Rap is required for ERK activation by isoproterenol. HEK293 cells were
transfected with the indicated cDNAs and treated with 10 mM isoproterenol for 3 min. Equivalent amounts of cell lysate were immunoprecipitated
using an agarose-coupled Myc antibody followed by an immune complex kinase assay with the location and phosphorylation of MBP shown by
autoradiography. A representative experiment can be seen in the upper panel (n 5 3). Lower panel, equal amounts of Myc-tagged protein were
loaded as evidenced by the Western blot probed with Myc antibody. B, data representing multiple myc-ERK immune complex kinase assays (from
A) are shown as -fold activation over basal (untreated cells) (n 5 3 6 S.D.).
In the unliganded, resting state, these receptors bind inac-
tive GDP-bound Gas subunits that are associated with specific
bg subunits. Upon ligand binding, exchange of GTP for GDP
converts a into its active GTP-bound state, causing it to be
released from the receptor, where it is free to bind to, and
activate, membrane-associated adenylate cyclases. At the same
time that Gas dissociates from the receptor, bg is released from
Gas and can activate effectors independently of Gas. bg signal-
ing from Gs-coupled receptors has not been reported. However,
bg release from Gi and Gq is well known to activate a number
of intracellular kinases, including phosphoinositol 3-kinase
(20, 21), phospholipase C (61), Src (16), and ERK (15, 62).
The ability of Gs-coupled receptors to modulate the MAP
kinase (or ERK) cascade provides a mechanism for cAMP-
coupled signaling pathways to regulate cell growth (3). The
best studied actions of cAMP on ERK signaling are inhibitory
and lead to a decrease in cellular proliferation (30–32). This is
achieved, in part, by a PKA-dependent phosphorylation of the
MAP kinase kinase kinase Raf-1 on serine 43, which uncouples
Raf-1 from its upstream activator Ras (30). In cells that express
the Raf isoform B-Raf (which does not contain a PKA site
corresponding to serine 43), cAMP can activate ERKs (9, 35,
63). Although this has been shown in multiple cell types, ad-
ditional factors may influence cAMPs ability to activate B-Raf.
Indeed, cAMP has also been reported to inhibit the activation of
B-Raf through a PKA phosphorylation near the kinase domain
itself. However, this effect is only seen in truncated proteins
lacking the N terminus of B-Raf (64). In cells that express a
truncated splice variant of B-Raf that also lacks the N termi-
nus, cAMPs inhibitory effects may predominate (65). However,
cAMP robustly activates the full-length B-Raf protein, which is
achieved via the activation of the small G protein Rap1 (9, 66,
67). Interestingly, Rap1 is also an antagonist of Ras-dependent
signaling (52, 68, 69) and blocks Ras-dependent activation of
Raf-1 (52, 70–72). Unlike Ras, Rap1 is activated by increased
cAMP levels via PKA. Recently, Rap1 activators have been
identified that can be directly activated by cAMP, suggesting
that cAMP can activate Rap1 via both PKA-dependent and
PKA-independent mechanisms (37, 38). The ability of b2AR to
inhibit ERK signals has been demonstrated in adipocytes (32)
and smooth muscle cells (31). Recently, b2AR has been shown
to activate ERKs in HEK293 cells (40, 41, 73). In this study, we
show that b2AR can activate ERKs in HEK293 cells by activat-
ing a Rap1/B-Raf pathway, while simultaneously blocking Ras-
dependent signals.
HEK293 cells are commonly used to examine signaling path-
ways downstream of transfected receptors (39–41, 74). We
show that these cells express endogenous b2AR and upon iso-
proterenol stimulation utilize b2AR to activate ERKs. This
activation shows an EC50 of roughly 1–3 mM, consistent with
other actions of isoproterenol, and is rapid and transient (43).
Its actions on ERKs are mimicked by forskolin and require
FIG. 7. b2AR activates B-Raf, but not Raf-1, via Rap1. A, HEK293 cells express B-Raf. Western blotting of equal amounts of protein were
used to represent cell lysates from various cell types: PC12 (1), HEK293 (2), Rat1 fibroblast (3), and PC3 (4). B, isoproterenol induces Rap1/B-Raf
association and B-Raf kinase activity. HEK293 cells were transfected with His-tagged Rap1 (His-Rap) or His-RapV12 cDNAs, serum-starved, and
treated with 10 mM isoproterenol for 3 min or left untreated, in the absence or presence of the PKA inhibitor, H89 as indicated. Equal amounts of
protein were passed over a nickel column, and eluates were probed by Western blotting for B-Raf (upper panel) and kinase activity using MEK-1
as a substrate (middle panel). Representative results are shown (n 5 3). The bottom panel indicates similar protein amounts of His-Rap per
treatment as assayed by Western blot. C, data representing multiple B-Raf kinase assays. Bars indicate -fold activation over basal (n 5 3 6 S.D.).
D, isoproterenol inhibits Ras/Raf-1 association. HEK293 cells were transfected with His-Ras, serum-starved, and treated with either 10 mM
isoproterenol for 3 min, 100 ng/ml EGF for 5 min, or pretreated with 10 mM isoproterenol for 5 min and then EGF. Equal amounts of protein lysate
underwent nickel affinity purification, and eluates were probed by Western blotting for Raf-1 (upper panel). The lower panel demonstrates similar
levels of His-Ras protein. E, isoproterenol inhibits Ras/B-Raf association. HEK293 cells were transfected with His-Ras, serum-starved, and
stimulated identically to Fig. 6D. Following nickel affinity purification, eluates were probed by Western blotting for B-Raf (upper panel). The lower
panel indicates similar levels of His-Ras.
PKA, suggesting the involvement of Gas and cAMP. Although
signaling via Gas is classically thought to be insensitive to PTx,
recent reports have demonstrated that b2AR can couple to
ERKs via PTx-sensitive pathways (41). These studies, which
utilized transiently transfected cDNAs encoding b2AR in
HEK293 cells, proposed a PKA-dependent switch in b2AR af-
finity from Gs to Gi. In our hands, PTx did not block b2AR’s
activation of ERKs, while blocking the action of known Gi-
coupled agents, including carbachol, lysophosphatidic acid, and
clonidine. It is possible that the ability of b2AR to couple to
PTx-sensitive pathways is dependent on elevated levels of
b2AR expression.
Both Ras-dependent and Rap1-dependent mechanisms of
b2AR’s activation of ERKs have been proposed (35, 40). Indeed,
we show that both Ras and Rap1 were activated by isoproter-
enol. Ras is activated rapidly and transiently, whereas Rap1
activation is slower and is sustained. This is similar to the
kinetics seen in other cell types, including PC12 cells (47) and
in platelets (75). Interestingly, the activation of Rap1, but not
Ras, required PKA. Forskolin, which acts downstream of Gas to
elevate cAMP, also activated Rap1 but did not activate Ras.
These data suggest that b2AR utilized distinct pathways to
activate Ras and Rap1. We propose that Rap1 is activated by
Gas (via cAMP and PKA), and that Ras is activated independ-
ently of Gas, possibly by a bg-dependent pathway. For Rap1,
PKA appears to act upstream of Rap1 itself, possibly through a
mechanism involving the Rap1 guanine-nucleotide exchanger
C3G (47). C3G is expressed in HEK293 cells and is distinct
from recently proposed exchangers like cAMP-GEFs (Epacs)
that appear to be activated by cAMP in a PKA-independent
manner (37, 38).
Surprisingly, only Rap1, but not Ras, was required for
b2AR’s activation of ERKs. Two agents that interfere with
Rap1 signaling, RapN17 and Rap1GAP1, were used. Overex-
pression of RapN17 is thought to sequester endogenous activa-
tors of Rap1, whereas Rap1GAP1 stimulates the GTPase ac-
tivity of endogenous Rap1 to terminate Rap1 signaling (9, 18,
76). RasN17 is a well characterized selective interfering mu-
tant of Ras (50, 77). These data suggest that, although both Ras
and Rap1 are activated by b2AR, only Rap1 is capable of trans-
mitting a signal to ERKs. The signal to ERKs is likely to be
B-Raf, since B-Raf is the only known MAP kinase kinase kinase
that can be activated by Rap1. Indeed, HEK293 cells express
the 96-kDa isoform of B-Raf that is activated by cAMP (9), and
endogenous B-Raf is recruited to Rap1 upon isoproterenol stim-
ulation, in a PKA-dependent manner. Both Raf-1 and B-Raf
have been shown to be efficiently recruited to Ras under the
appropriate conditions (54, 66, 78, 79). However, neither Raf-1
nor B-Raf were recruited to Ras by isoproterenol treatment,
although Ras was GTP-loaded (activated) at the time point
used for this study. The inability of Ras to couple to Raf ex-
plains why b2AR’s activation of ERK was independent of Ras.
Isoproterenol not only did not induce Ras association with
effectors, it reversed the ability of Ras to recruit both Raf-1 and
B-Raf following EGF stimulation. For Raf-1, this may be due to
the phosphorylation of Raf-1 at serine 43 by PKA, which dis-
sociates Raf-1 from activated Ras. However, the ability of iso-
proterenol to block the recruitment of B-Raf to Ras cannot be
explained by this mechanism and suggests that an additional
action of PKA is antagonizing Ras function, in general. Indeed,
cAMP can also block recruitment of B-Raf to Ras (data not
shown). A potential mediator of this effect is Rap1 itself. We
propose a model in which Rap1 activation by PKA has two
opposing functions in B-Raf/Raf-1-expressing cells; the activa-
tion of B-Raf and the antagonism of Ras. The net effect of these
two actions will depend on the relative levels of Rap1 as well as
B-Raf and Raf-1 in each cell type.
Although we show that activated Ras cannot activate ERKs
in these cells, the mechanism by which Ras was activated by
b2AR in these cells is not known. Recently, the ability of b2AR
to activate Ras-dependent signaling has been suggested by
Lefkowitz and colleagues. In their model, transiently trans-
fected b2AR utilized a PTx-sensitive pathway to transactivate
the endogenous EGF receptor. However, using cells expressing
endogenous b2AR, we show that isoproterenol’s ability to acti-
vate either ERK or Ras did not require EGF receptor kinase
FIG. 8. ERK/Ras activation by b2AR does not require EGF receptor phosphorylation. A, isoproterenol-mediated activation of ERKs is
EGF receptor-independent. Serum-starved HEK293 cells were pretreated with 200 nM AG1478 for 20 min, followed by 10 mM isoproterenol
stimulation for the indicated times. As a control, cells were also treated with 100 ng/ml EGF for 5 min. Lysates were subjected to Western blotting
using pERK antibodies (upper panel) or ERK2 antibody (lower panel) to confirm equal protein amounts of cell lysate were utilized. B, isoproterenol
stimulation of Ras is EGF receptor-independent. HEK293 cells were serum-starved and pretreated with 200 nM AG1478 for 20 min, followed by
a 3-min stimulation with 10 mM isoproterenol. Stimulation with 100 ng/ml EGF for 5 min was used as a control for Ras activation. Equal amounts
of cell lysate were incubated with pre-coupled GST-Raf1RBD and analyzed by Western blot for GTP-loaded Ras. C, isoproterenol-mediated
activation of Ras is insensitive to PTx. HEK293 cells were pretreated with 100 ng/ml PTx for 16 h and then stimulated with either 10 mM
isoproterenol for 3 min or 10 mM carbachol for 5 min, as indicated. Equal amounts of cell lysate were incubated with pre-coupled GST-Raf1RBD
and analyzed by Western blot for GTP-loaded Ras.
activity. In addition, Ras activation by isoproterenol was not
blocked by PTx. Since Ras activation by isoproterenol was not
sensitive to H89, we propose that Ras activation by b2AR is not
mediated by PKA, Gi, or EGF receptor. We suggest that bg
subunits, which have been shown to activate Ras in many
systems, may contribute to b2AR’s actions. The ability of both
a and bg to regulate ERK signaling following receptor binding
may be a common mechanism of coordinating signals to ERKs.
For example, hormones that are able to activate Gi-coupled
pathways have been shown to modulate ERKs via both bg and
a subunits. bg activates Ras via phosphoinositol 3-kinase g (21)
and Gai activates a Rap1GAPII to inactivate Rap1 (19). Here,
we show a second mechanism of Rap1 regulation by a subunits,
the activation of Rap1 via elevation of intracellular cAMP lev-
els. Although PKA-independent regulation of Rap1 by cAMP
has been proposed (37, 38), the data shown here demonstrate
that cAMP requires PKA to activate Rap1 in HEK293 cells, as
well as other cell types (9, 35, 39).
The Rap1/B-Raf pathway identified here may be an impor-
tant mechanism by which b2AR stimulates ERKs in multiple
systems. This may be especially true in neurons and in prostate
cells that express high levels of B-Raf and where cAMP signal-
ing to ERKs has been shown to require Rap1 (9, 63, 80). For
example, b2AR-dependent models of long term potentiation in
hippocampal neurons has recently been shown to require ERKs
(81) and deficits in this form of long term potentiation have
been identified in transgenic mice deficient in hippocampal
Rap1 signaling (82). Taken together, these studies suggest that
the ability of Gs-coupled receptors to activate or inhibit ERKs
may depend, in part, on the expression of B-Raf (51). Although
the activation of Rap1 may have a significant positive effect on
ERK signaling in B-Raf-expressing cells, one can speculate that
the activation of Rap1 by Gs-coupled receptors may antagonize
Ras-dependent signaling to ERKs in cells that do not express
B-Raf.
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